Trial Profile
A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Advanced breast cancer; Bone metastases; Multiple myeloma; Prostate cancer
- Focus Adverse reactions
- Sponsors Bayer; Bayer HealthCare
- 08 Mar 2024 This trial has been completed in Germany, According to European Clinical Trials Database record.
- 19 Feb 2024 Status changed from active, no longer recruiting to completed.
- 06 Oct 2023 This trial has been completed in Sweden and Czech republic , according to European Clinical Trials Database.